Viking Therapeutics (VKTX) Assets Average (2015 - 2026)
Viking Therapeutics (VKTX) posted Assets Average of $565.1 million for Q2 2026, down 14.64% sequentially from $662.0 million in Q1 2026, and down 33.32% YoY from $847.4 million in Q2 2025.
Viking Therapeutics (VKTX) Assets Average (2015 - 2026) Analysis & Trends
Viking Therapeutics has reported Assets Average for 12 years, with the latest figure at $565.1 million in Q2 2026.
- Quarterly Assets Average fell 33.32% year-over-year to $565.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $565.1 million (down 33.32% YoY) and the FY2025 annual result came in at $812.0 million, up 27.2% from the prior year.
- Assets Average fell to $565.1 million in Q2 2026 per VKTX's latest filing, from $662.0 million in the prior quarter.
- Over five years, Assets Average peaked at $957.2 million in Q2 2024 and troughed at $159.7 million in Q1 2023.
- A 5-year average of $550.0 million and a median of $613.5 million in 2026 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2026: Assets Average jumped 318.26% in 2024, then plunged 33.32% in 2026.
- Over 5 years, Assets Average stood at $167.6 million in 2022, then soared by 124.08% to $375.6 million in 2023, then jumped by 145.78% to $923.1 million in 2024, then declined by 21.18% to $727.6 million in 2025, then declined by 22.33% to $565.1 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $565.1 million, $662.0 million, and $727.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | 565.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 565.07 Mn |
| Mar 31, 2026 | 661.99 Mn |
| Dec 31, 2025 | 727.57 Mn |
| Sep 30, 2025 | 783.63 Mn |
| Jun 30, 2025 | 847.42 Mn |
| Mar 31, 2025 | 887.66 Mn |
| Dec 31, 2024 | 923.10 Mn |
| Sep 30, 2024 | 942.36 Mn |
| Jun 30, 2024 | 957.18 Mn |
| Mar 31, 2024 | 668.00 Mn |
| Dec 31, 2023 | 375.58 Mn |
| Sep 30, 2023 | 391.68 Mn |
| Jun 30, 2023 | 275.79 Mn |
| Mar 31, 2023 | 159.71 Mn |
| Dec 31, 2022 | 167.61 Mn |
| Sep 30, 2022 | 174.10 Mn |
| Jun 30, 2022 | 188.27 Mn |
| Mar 31, 2022 | 202.85 Mn |
| Dec 31, 2021 | 217.57 Mn |
| Sep 30, 2021 | 231.16 Mn |